The startup develops a fusion protein therapy that targets chronic and infectious diseases by harnessing the body's innate immune system to induce immunogenic cell death in unwanted cells, such as cancer. This technology not only eliminates targeted cells but also trains the immune system to prevent their recurrence, enhancing the effectiveness of cancer treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Many chronic and infectious diseases, including cancer, evade the body's immune system, leading to persistent infections and tumor growth. Current therapies often fail to fully eradicate diseased cells or prevent recurrence, necessitating more effective and targeted approaches.
Solution
This startup is developing a fusion protein therapy designed to harness the body's innate immune system to combat chronic and infectious diseases. The therapy induces immunogenic cell death (ICD) in targeted cells, such as cancer cells, triggering a robust immune response. By inducing ICD, the treatment not only eliminates the targeted cells but also stimulates the immune system to recognize and prevent their recurrence, potentially leading to more durable and effective therapeutic outcomes.
Target Audience
The primary target audience includes patients with chronic diseases, infectious diseases, and various types of cancer, as well as oncologists and infectious disease specialists seeking more effective treatment options.
Features
- Fusion protein design for targeted delivery to diseased cells.
- Induction of immunogenic cell death (ICD) to stimulate a systemic anti-tumor immune response.
- Potential for long-term immunity and prevention of disease recurrence.